Successfully reported this slideshow.

Public Device & Biopharma Ophthalmology Company Showcase - Omeros

1

Share

Upcoming SlideShare
Opthea
Opthea
Loading in …3
×
1 of 10
1 of 10

Public Device & Biopharma Ophthalmology Company Showcase - Omeros

1

Share

Download to read offline

Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.

Presenter:
Leonard M. Blum, Chief Business & Commercial Officer


Powered by:
Healthegy

For more ophthalmology innovation
Visit us at www.ois.net

Public Device & Biopharma Ophthalmology Company Showcase - Omeros at OIS@AAO 2016.

Presenter:
Leonard M. Blum, Chief Business & Commercial Officer


Powered by:
Healthegy

For more ophthalmology innovation
Visit us at www.ois.net

More Related Content

Related Books

Free with a 14 day trial from Scribd

See all

Public Device & Biopharma Ophthalmology Company Showcase - Omeros

  1. 1. 1 Next-Generation Therapeutics Transforming Patient Care Today Leonard M. Blum Chief Business and Commercial Officer Ophthalmology Innovation Summit Chicago, IL October 13, 2016
  2. 2. 2 Safe Harbor This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of Omeros Corporation. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros’actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros’unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments, litigation and other factors. For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. Except as required by law, Omeros undertakes no obligation to update any forward-looking statements in this presentation, whether as a result of new information, future events or otherwise.
  3. 3. 3 Ophthalmic Surgery: OMIDRIA®  Intraocular product to prevent miosis and to reduce postoperative ocular pain in adults undergoing cataract surgery or refractive lens exchange  NSAID-containing product for intraocular administration during cataract surgery OMIDRIA is the first and only FDA-approved…
  4. 4. 4 Early Focus at Launch: Patient Access to OMIDRIA®  OMIDRIA was granted pass-through status by CMS – Paid separately (ASP + 6%) outside of the facility’s packaged payment for cataract surgery – Budget-neutral to the healthcare system  Covered and reimbursed by 100% of Medicare Administrative Contractors  Expanding coverage by Medicare Advantage plans and commercial payers Patient access further expanded through OMIDRIAssure™ and 340b programs
  5. 5. 5 OMIDRIA® Net Revenue 3Q 2015 4Q 2015 1Q 2016 2Q 2016 $3.2 M $6.7 M $7.2 M $10.0 M Net Revenue by Quarter
  6. 6. 6 OMIDRIA® Real-World Evidence Shows Improved Outcomes  Decrease in complications associated with small pupils1  Reduction in usage of pupil- expanding devices1-3  Prevention of miosis during femtosecond laser-assisted surgery4  Shorter surgical times1,2  Improvement in uncorrected visual acuity on postoperative Day 11 1. Rosenberg E, et al. Abstract presented at 2016 American Society of Cataract and Refractive Surgeons. 2016. 2. Visco D. Abstract presented at 2016 American Society of Cataract and Refractive Surgeons. 2016. 3. Bucci F. Abstract presented at 2016 Association for Research in Vision and Ophthalmology. 2016. 4. Gayton J, et al. Manuscript submitted for publication. Post-launch, case-controlled, single-center analyses, with and without femtosecond laser, resulted in statistically significant . . . Additional manuscripts in preparation include effects of OMIDRIA on prostaglandin inhibition and need for topical NSAIDs
  7. 7. 7 Marketed OMIDRIA® Driving the Pipeline Product/Program Targeted Disease Pre-clinical Phase 1 Phase 2 Phase 3 Marketing Approval Economic Rights Clinical Programs MASP-2 (OMS721) - Lectin Pathway Disorders Atypical Hemolytic Uremic Syndrome MASP-2 (OMS721) - Lectin Pathway Disorders IgA Nephropathy and Other Renal Diseases; TMAs PDE10 (OMS824) - CNS Disorders Huntington's and Schizophrenia PPARγ (OMS405) - Addiction Opioid and Nicotine Addiction OMS201 - Urology Ureteroscopy Preclinical Programs PDE7 (OMS527) - CNS Disorders Addictions and Compulsive Disorders; Movement Disorders Plasmin (OMS616) - Bleeding Disorders Surgical and Traumatic Bleeding MASP-3 (OMS906) – Alternative Pathway Disorders PNH and a Wide Range of Other Alternative Pathway Disorders GPR17, GPR101, GPR151, GPR161, GPR174, GPR183 Demyelinating Disorders; Eating Disorders; Pain; Breast Cancer; Osteoporosis and EBV; T-Regs GPCR Platform CNS, Metabolic, CV, Oncologic, Musculoskeletal & Other Disorders Antibody Platform Metabolic, CV, Oncologic, Musculoskeletal & Other Disorders
  8. 8. 8 OMS721 Targets Mannan-Binding Lectin-Associated Serine Protease-2, the Effector Enzyme of the Lectin Pathway Classical Pathway Alternative Pathway Coagulation Lectin Pathway Platelet Activation Leukocyte Recruitment Cell Lysis Immune Complex Infection, Tissue Injury C3a Factor D Thrombin OMS721 MASP-2C1r/s C4, C2 C4b/2a C3 C3b Factor B C5a MAC* C5b C1q MBL*, Ficolins, CL-11 C5 *MAC = membrane attack complex *MBL = mannose-binding lectin OMS721 Phase 3  Atypical hemolytic uremic syndrome (aHUS) Phase 2  Complement-associated nephropathies  Thrombotic microangiopathies Ophthalmic Indications  AMD  Uveitis  Diabetic macular edema
  9. 9. 9 Next-Generation Therapeutics Transforming Patient Care Today Leonard M. Blum Chief Business and Commercial Officer Ophthalmology Innovation Summit Chicago, IL October 13, 2016
  10. 10. 10

×